Intramammary infusion of a live culture ofLactococcus lactisfor treatment of bovine mastitis: comparison with antibiotic treatment in field trials

2008 ◽  
Vol 75 (3) ◽  
pp. 365-373 ◽  
Author(s):  
Katja Klostermann ◽  
Fiona Crispie ◽  
James Flynn ◽  
R Paul Ross ◽  
Colin Hill ◽  
...  
Keyword(s):  
Antibiotic Treatment ◽  
Bovine Mastitis ◽  
Clinical Signs ◽  
Experimental Period ◽  
Treated Group ◽  
Field Trials ◽  
Clinical Mastitis ◽  
Post Treatment ◽  
Cell Counts ◽  
Live Culture

A treatment containing a live food-grade organism,Lactococcus lactisDPC3147, was compared with conventional antibiotic therapy for its potential to treat bovine chronic subclinical or clinical mastitis in two separate field trials. Effects on disease symptoms and bacteriology were monitored in response to infusion with the culture in each trial. In the first trial, the live culture treatment was compared with an intramammary antibiotic (n=11 quarters for each treatment). Results from this small trial demonstrated that the live culture had potential to be as effective at eliminating chronic subclinical infections as an antibiotic treatment. By day 12, 7 of the 11 quarters treated with the live culture were pathogen-free compared with 5 of the 11 antibiotic-treated infected quarters. Somatic cell counts (SCC) remained relatively unchanged regardless of treatment: average log SCC pre- and post-treatment in the lactococci-treated group were 6·33±0·41 (day 0) and 6·27±0·43 cells/ml (day 12) and average log SCC pre- and post-treatment in the antibiotic-treated group were 6·34±0·37 and 6·22±0·46 cells/ml on day 0 and on day 12, respectively. In the second trial, the live culture was compared with an intramammary antibiotic for the treatment of naturally occurring clinical mastitis cases (n=25 quarters for each treatment). Following a 14-d experimental period, similar bacteriological responses were observed in 7 out of 25 live culture treated quarters and 9 out of 25 antibiotic-treated quarters. Additionally, 15 of 25 cases treated with the culture and 18 of 25 cases treated with the antibiotic did not exhibit clinical signs of the disease following treatment. The results of these trials suggest that live culture treatment withLc. lactisDPC3147 may be as efficacious as common antibiotic treatments in some instances.

Intramammary infusion of a live culture for treatment of bovine mastitis: effect of live lactococci on the mammary immune response

2008 ◽  
Vol 75 (3) ◽  
pp. 374-384 ◽  
Author(s):  
Fiona Crispie ◽  
Mercedes Alonso-Gómez ◽  
Collette O'Loughlin ◽  
Katja Klostermann ◽  
James Flynn ◽  
...  
Keyword(s):  
Immune Response ◽  
Lactococcus Lactis ◽  
Acute Phase Proteins ◽  
Bovine Mastitis ◽  
Field Trials ◽  
Initial Field ◽  
Amyloid A ◽  
Probiotic Treatment ◽  
Post Infusion ◽  
Live Culture

In the accompanying article, we demonstrated that a live culture ofLactococcus lactiscompares favourably with antibiotics for treatment of bovine mastitis in two initial field trials. In an effort to explain the mechanism involved, this study investigated the effect of culture administration on the local immune response. In this respect we initially observed that infusion of the live cultureLactococcus lactisstimulated substantial recruitment of polymorphonucleocytes (PMN) and lymphocytes to the udder. For instance, in one assay, quarters infused with the probiotic experienced a dramatic increase (~20 000-fold) in neutrophils over the first 48-h period from an average value of 83·6 cells/ml pre-treatment to 1·78×106 cells/ml 48 h post-infusion. Levels of the acute phase proteins haptaglobin and milk amyloid A were also elevated significantly in comparison with controls following infusion of the culture. The results of flow cytometric assays also demonstrated that while infusion of a live lactococcal culture led to an enhanced recruitment of PMN to the udder (from 1·85×104 cells/ml pre-infusion to 1·45×106 cells/ml 24 h post-infusion) cell-free supernatant from the same culture was not able to do so, indicating that liveLc. lactiscan specifically trigger the mammary immune response to elicit PMN accumulation. These results suggest that the mechanism responsible for this probiotic treatment of mastitis is associated with stimulation of the host intramammary immune system.

scholarly journals Development of an improved Streptococcus uberis experimental mastitis challenge model using different doses and strains in lactating dairy cows

2015 ◽  
Vol 82 (4) ◽  
pp. 470-477 ◽  
Author(s):  
Manouchehr Khazandi ◽  
Patricia Eats ◽  
Darren Trott ◽  
Esmaeil Ebrahimie ◽  
Jeanette Perry ◽  
...  
Keyword(s):  
Success Rate ◽  
Bovine Mastitis ◽  
Clinical Signs ◽  
Clinical Mastitis ◽  
Clinical Findings ◽  
Infection Model ◽  
Treatment Groups ◽  
Streptococcus Uberis ◽  
Reliable Model ◽  
High Doses

Developing a reliable mastitis challenge infection model is required to test new intramammary antimicrobial preparations, other novel bovine mastitis treatments, and study mastitis pathogenesis. Three treatment groups of Holstein Friesian cows in active lactation were administered two doses (104 and 106 cfu/quarter) on a single occasion with one of the three Streptococcus uberis strains (BFR6019, MFF1283 and SA002) suspended in 5 ml of sterile PBS, administered via intramammary inoculation immediately after milking. All quarters that were challenged with S. uberis strains MLF1283 and BFR6019 showed clinical signs of mastitis on day 1 and 2 after the challenge. Strain SA002 had a lower rate of inducing clinical mastitis which was detected later than day 3 after the challenge. We successfully developed a rapid and reliable model for inducing experimental S. uberis mastitis with 100% success rate in cows in active lactation. On the basis of the correlation results between strains, RAPD fingerprinting results, clinical findings, and a 100% success rate of mastitis induction for low and high doses S. uberis strains MLF1283 and BFR6019, strain virulence seems to be a more important effect than challenge dose in induction of clinical mastitis following experimental challenge.

scholarly journals Therapeutic efficacy of isometamidium chloride in the treatment of Trypanosoma congolense infection in Sokoto Red bucks

2020 ◽  
pp. 40-43
Keyword(s):  
Body Weight ◽  
Therapeutic Efficacy ◽  
Clinical Signs ◽  
Treated Group ◽  
Trypanosoma Congolense ◽  
Post Treatment ◽  
The Body ◽  
Group I ◽  
Drug Concentrations ◽  
Group Ii

Introduction: Treatment of animal trypanosomiasis using isometamidium chloride (ISM) is largely done with 1% solution however, 2% solution has been found to be more effective. In this study, therapeutic efficacy of ISM drug concentrations was studied in Trypanosoma congolense infected Sokoto Red Bucks (SRB). The aim of the study was to determine the efficacy of the curative (1%) and prophylactic (2%) concentrations of ISM in the treatment of experimentally infected SRB with Trypanosoma congolense. Methods: Twelve SRB were divided into three groups of four animals each: Group I (1% ISM treated), Group II (2% ISM treated) at the dose rate of 0.5 mg/kg body weight intramuscularly and Group III (uninfected and untreated-Control). Groups I and II bucks were each inoculated intravenously with approximately 1x106 T. congolense. Clinical signs, rectal temperature, body weight, packed cell volume (PCV), total white blood cell count (TWBCC) were monitored. Wet-mount and micro haematocrit centrifugation technique (HCT) were used to monitor the parasitaemia post-infection and post-treatment. Seven days post-treatment the blood from the treated groups were sub-inoculated into mice. Results: Group I had relapse of the infection two weeks post-treatment while no relapse of the infection was observed in the Group II till five weeks post-treatment. Significant (p < 0.05) changes in the PCV, WBCC and body weight were properly recorded as well as the clinical signs and the body weight. Significance: The 2% ISM confers better and longer cure than the 1% ISM in treating trypanosomosis in goat.

Effects of intramammary inoculation ofLactobacillus perolensCRL1724 in lactating cows’ udders

2011 ◽  
Vol 79 (1) ◽  
pp. 84-92 ◽  
Author(s):  
Ignacio D Frola ◽  
Matías S Pellegrino ◽  
María C Espeche ◽  
José A Giraudo ◽  
María EF Nader-Macias ◽  
...  
Keyword(s):  
Bovine Mastitis ◽  
Clinical Signs ◽  
Probiotic Properties ◽  
Lactating Cows ◽  
Cell Counts ◽  
Major Pathogens ◽  
Adhesion Index ◽  
Teat Canal

Bovine mastitis is the most important infectious disease on dairy farms. Conventional antibiotic therapy is often unsatisfactory and alternative treatments are continually under investigation.Lactobacillus (Lb.) perolensCRL 1724 andLactobacillus plantarumCRL 1716 were previously isolated from milk of dairy cows and selected according to their potential probiotic properties. In the present work the in-vitro capacity ofLactobacillusstrains to adhere to bovine teat canal epithelial cells (BTCEC) and to inhibit and co-aggregate 14 mastitis-causing pathogens (MCPs) was investigated. The effect ofLb. perolensCRL 1724 after intramammary inoculation in lactating cows was evaluated through determination of clinical signs of mastitis, milk appearance, somatic cell counts andLb. perolensCRL 1724 recovery from milk.Lb. perolensCRL 1724 was able to inhibit 12 of 14 MCPs (85·7%) in vitro, especially those considered to be major pathogens. In addition,Lb. perolensCRL 1724 co-aggregated with all of them.Lb. plantarumCRL 1716 was able to inhibit 7 of 14 MCPs (50%) in vitro and showed co-aggregation ability similar toLb. perolensCRL 1724.Lb. perolensCRL 1724 showed a higher efficacy of adhesion to BTCEC (values of percentage of adhesion and adhesion index of 75% and 14·4, respectively) thanLb. plantarumCRL 1716 (37% and 7·4, respectively).Lb. perolensCRL 1724 was recovered from all mammary quarters and no clinical signs or teat damage were observed after the inoculation of 106cfu/ml. The udders presented a normal aspect and there were no changes in the appearance of the milk. The results obtained will serve as the basis for further trials to evaluate the potential ofLb. perolensCRL 1724 to be included in a non-antibiotic formulation for the prevention of bovine mastitis.

Evaluation of the efficacy of systemic danofloxacin in the treatment of induced acuteEscherichia colibovine mastitis

2008 ◽  
Vol 75 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Bernard Poutrel ◽  
Michael R Stegemann ◽  
Olivier Roy ◽  
Francis Pothier ◽  
Nicola Tilt ◽  
...  
Keyword(s):  
Milk Production ◽  
Pathogenic Bacteria ◽  
Bovine Mastitis ◽  
Clinical Signs ◽  
Saline Control ◽  
Intravenous Route ◽  
Post Inoculation ◽  
General Behaviour ◽  
Cell Counts ◽  
Clinical Scores

The objective was to evaluate the efficacy of a single dose of danofloxacin (6 mg/kg bodyweight) given by the intravenous route for the treatment of acute bovine mastitis induced by intra-cisternal infusion of anEscherichia colistrain (26 cfu into one rear quarter of each cow). Twenty-three Prim'Holstein lactating cows were inoculated. To be challenged, the mammary glands had to be productive, free of pathogenic bacteria, and with somatic cell counts (SCC) of <200 000 cells/ml. The cows were treated on an individual basis when predetermined criteria involving both systemic and local clinical signs were satisfied. Allocation to treatment, danofloxacin or negative saline control, was performed according to a randomized treatment allocation plan. Monitoring during a 21-d period after inoculation included individual clinical examination, bacteriological examination and determination of SCC.Esch. coliwas isolated from the milk of all inoculated quarters at the first milking post-inoculation and, together with reference to the clinical scores; the challenge was considered to be successful in 20 of the 23 cows. On study day 7 bacteriological cure rates with danofloxacin and saline control were 89% (8/9) and 44% (4/9) respectively. On days 14 and 21 all milk samples that could be collected were negative forEsch. coliin both groups of animals. Beneficial statistically significant differences were found at the end of the observation period (days 19–21 post treatment) between cows treated with danofloxacin and saline for SCC (P=0·0091) and earlier in the study for milk production (P=0·0003) and udder inflammation (P=0·004). Obvious beneficial trends were recorded in the danofloxacin group for rectal temperature, milk quality, general behaviour and appetite. Danofloxacin-treated cows showed statistically significant lower local clinical scores and a more rapid return to pre-inoculation values. It was concluded that systemically administered danofloxacin is effective in terms of bacteriological results, milk production and both systemic and local signs when used in the treatment of induced acuteEsch. colimastitis. Danofloxacin hastens recovery and return to productivity compared with potential self cure.

scholarly journals Administration of a live culture ofLactococcus lactisDPC 3147 into the bovine mammary gland stimulates the local host immune response, particularlyIL-1β andIL-8gene expression

2009 ◽  
Vol 76 (3) ◽  
pp. 340-348 ◽  
Author(s):  
Christine Beecher ◽  
Mairéad Daly ◽  
Donagh P Berry ◽  
Katja Klostermann ◽  
James Flynn ◽  
...  
Keyword(s):  
Immune Response ◽  
Mammary Gland ◽  
Antibiotic Therapy ◽  
Bovine Mastitis ◽  
Field Trials ◽  
Immune Gene ◽  
Pronounced Increase ◽  
Post Infusion ◽  
Local Host ◽  
Live Culture

Mastitis is one of the most costly diseases to the dairy farming industry. Conventional antibiotic therapy is often unsatisfactory for successful treatment of mastitis and alternative treatments are continually under investigation. We have previously demonstrated, in two separate field trials, that a probiotic culture,Lactococcus lactisDPC 3147, was comparable to antibiotic therapy to treat bovine mastitis. To understand the mode of action of this therapeutic, we looked at the detailed immune response of the host to delivery of this live strain directly into the mammary gland of six healthy dairy cows. All animals elicited signs of udder inflammation 7 h post infusion. At this time, clots were visible in the milk of all animals in the investigation. The most pronounced increase in immune gene expression was observed inInterleukin(IL)-1β andIL-8, with highest expression corresponding to peaks in somatic cell count. Infusion with a live culture of aLc. lactisleads to a rapid and considerable innate immune response.

Efficacy of homeopathic and antibiotic treatment strategies in cases of mild and moderate bovine clinical mastitis

2010 ◽  
Vol 77 (4) ◽  
pp. 460-467 ◽  
Author(s):  
Christina Werner ◽  
Axel Sobiraj ◽  
Albert Sundrum
Keyword(s):  
Antibiotic Treatment ◽  
Treatment Strategy ◽  
Clinical Signs ◽  
Treatment Strategies ◽  
Placebo Treatment ◽  
Clinical Mastitis ◽  
Cure Rate ◽  
Homeopathic Treatment ◽  
The Difference ◽  
Pre Treatment

The objective of this clinical control trial was to examine the effectiveness of the classical homeopathic treatment strategy in cases of mild and moderate bovine clinical mastitis in comparison with antibiotic and placebo treatments. Owing to characteristics of the selected herds, only cases of clinical mastitis caused by environmental pathogens and clinical cases with negative bacteriological result in the pre-treatment milk sample were included in the trial. A total of 136 lactating dairy cows with 147 affected quarters from four herds in Germany were randomly allocated to three treatment groups. The cows were examined on days 0, 1, 2 and on days 7, 14, 28 and 56 post initial infection to assess clinical signs. Simultaneously, with the exception of days 1 and 2, quarter milk samples for laboratory examinations (bacteriology, somatic cell count) were collected to assess bacteriological and cytological cure rates. On days 28 and 56, treatment strategies did not differ significantly with respect to the clinical outcomes and the total cure rate in cases of bacteriological negative mastitis (n=56). In cases of pathogen-positive mastitis (n=91), the cure rate after 4 and 8 weeks was similar between the two treatment strategies, homeopathy and antibiotic treatment, but the difference between the homeopathic and the placebo treatment at day 56 was significant (P<0·05). The results indicate a therapeutic effect of homeopathic treatment in cases of mild and moderate clinical mastitis. However, independent of treatment strategy and bacteriological status, the total cure rate was on a low level, revealing limitations in the effectiveness of both antibiotic and homeopathic treatment strategies.

scholarly journals Prevalence of Bovine Mastitis in the Western Region of Cameroon

2021 ◽  
pp. 1-5
Author(s):  
Müller FOTSAC DZOUSSE ◽  
◽  
Marc K. KOUAM ◽  
Keyword(s):  
Bovine Mastitis ◽  
Clinical Signs ◽  
Subclinical Mastitis ◽  
Clinical Mastitis ◽  
Feeding Method ◽  
Lactating Cows ◽  
Stage Of Lactation ◽  
California Mastitis Test ◽  
Farm Type ◽  
Age Range

Mastitis is the major disease in milking cows causing huge losses to the dairy industry worldwide. It is in view to contribute to the eradication of this pathology that the present study was carried out in cattle farms of the West Region of Cameroon from March 2020 to November 2020. A total of 473 lactating cows of local and improved breeds were screened for mastitis. Screening for clinical and sub-clinical mastitis was based on the observation of clinical signs and on the use of the California Mastitis Test (CMT) respectively. The overall prevalence was 34.88%, among which 9.72% and 25.16% represented clinical and subclinical mastitis respectively. In summary, the factors influencing the occurrence of mastitis were: the divisions surveyed (p<0.001), breed type (p=0.003), age range (p<0,001), farm type (p=0.05), soil type (p<0,001), cleaning frequency (p<0.001), feeding method (p<0.001), hygiene of udder (p=0.05) and stage of lactation (p=0.02). The results obtained allow us to recommend an improvement of the breeding conditions to prevent mastitis, because once mastitis appears in a farm, it becomes very difficult to eradicate it.

scholarly journals Antimicrobial susceptibility profile of Streptococcus agalactiae strains isolated from bovine mastitis

2021 ◽  
Vol 58 ◽  
pp. e178109
Author(s):  
Geraldo Márcio da Costa ◽  
Núbia Aparecida Ribeiro ◽  
Maysa Serpa Gonçalves ◽  
Juliana Rosa da Silva ◽  
Dircéia Aparecida da Costa Custódio ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Streptococcus Agalactiae ◽  
Bovine Mastitis ◽  
Clinical Mastitis ◽  
Penicillin G ◽  
Dairy Herds ◽  
High Frequencies ◽  
Intramammary Infections ◽  
Dry Cow Therapy ◽  
Cell Counts

Bovine mastitis is the most important disease of dairy herds worldwide. Its main etiologic agents are bacteria, including Streptococcus agalactiae. The importance of this agent in bovine mastitis is because it is highly contagious and has a high impact on the occurrence of clinical mastitis cases and in the increase of the bulk milk somatic cell counts. The dry cow therapy and the treatment of the clinical mastitis cases stand out among the measures to control intramammary infections in cows. However, these strategies require knowledge about the antimicrobial susceptibility of the causal microorganisms. Thus, this study aimed to evaluate the antimicrobial susceptibility of 89 S. agalactiae strains isolated from bovine mastitis between the years 2004 and 2008 in dairy herds from Campo das Vertentes region, Minas Gerais State, Brazil. The disc diffusion technique was used and the antimicrobials currently used in mastitis therapy were tested. The isolates tested showed 100% susceptibility to chloramphenicol, ceftiofur, cefotaxime, enrofloxacin, and cefquinome. High frequencies of susceptibility (>95%) were also observed for the beta-lactams (penicillin G, ampicillin, and oxacillin), cephalosporins (cephalotin, ceftiofur, cefotaxime, cefoperazone, and cefquinome), florfenicol, gentamicin, lincomycin, nitrofurantoin, and sulfamethoprim. The strains showed high frequencies of resistance to neomycin (15.74%), and tetracycline (21.35%). Multidrug resistance was detected in 2.25% of the tested isolates. The results pointed to variations in the antimicrobial susceptibility profiles of the studied strains and the importance of the use of the susceptibility tests to determine the correct antimicrobial to be applied in the treatment of bovine mastitis caused by S. agalactiae. The high frequencies of resistance observed to some antimicrobials, such as neomycin and tetracycline, commonly used in the treatment of mastitis and other pathologies, highlighted the need for more judicious use of antimicrobials on dairy farms.

scholarly journals Bacillus velezensis AP183 Inhibits Staphylococcus aureus Biofilm Formation and Proliferation in Murine and Bovine Disease Models

2021 ◽  
Vol 12 ◽  
Author(s):  
Sayma Afroj ◽  
Andrew D. Brannen ◽  
Shamima Nasrin ◽  
Abdulaziz Al Mouslem ◽  
Terri Hathcock ◽  
...  
Keyword(s):  
Biofilm Formation ◽  
Tracheostomy Tube ◽  
Bovine Mastitis ◽  
Treated Group ◽  
Clinical Mastitis ◽  
Mammary Tissue ◽  
Disease Models ◽  
High Dose ◽  
Post Inoculation

The increasing frequency of S. aureus antimicrobial resistance has spurred interest in identifying alternative therapeutants. We investigated the S. aureus-inhibitory capacity of B. velezensis strains in mouse and bovine models. Among multiple B. velezensis strains that inhibited S. aureus growth in vitro, B. velezensis AP183 provided the most potent inhibition of S. aureus proliferation and bioluminescence in a mouse cutaneous wound (P = 0.02). Histology revealed abundant Gram-positive cocci in control wounds that were reduced in B. velezensis AP183-treated tissues. Experiments were then conducted to evaluate the ability of B. velezensis AP183 to prevent S. aureus biofilm formation on a tracheostomy tube substrate. B. velezensis AP183 could form a biofilm on a tracheostomy tube inner cannula substrate, and that this biofilm was antagonistic to S. aureus colonization. B. velezensis AP183 was also observed to inhibit the growth of S. aureus isolates originated from bovine mastitis cases. To evaluate the inflammatory response of mammary tissue to intramammary inoculation with B. velezensis AP183, we used high dose and low dose inocula in dairy cows. At the high dose, a significant increase in somatic cell count (SCC) and clinical mastitis was observed at all post-inoculation time points (P &lt; 0.01), which resolved quickly compared to S. aureus-induced mastitis; in contrast, the lower dose of B. velezensis AP183 resulted in a slight increase of SCC and no clinical mastitis. In a subsequent experiment, all mammary quarters in four cows were induced to have grade 1 clinical mastitis by intramammary inoculation of a S. aureus mastitis isolate; following mastitis induction, eight quarters were treated with B. velezensis AP183 and milk samples were collected from pretreatment and post-treatment samples for 9 days. In groups treated with B. velezensis AP183, SCC and abundance of S. aureus decreased with significant reductions in S. aureus after 3 days post-inoculation with AP183 (P = 0.04). A milk microbiome analysis revealed significant reductions in S. aureus relative abundance in the AP183-treated group by 8 days post-inoculation (P = 0.02). These data indicate that B. velezensis AP183 can inhibit S. aureus biofilm formation and its proliferation in murine and bovine disease models.

Sign in / Sign up

Export Citation Format

Share Document